STAT+: With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant
Merck will continue to search out more acquisitions after its $11 billion purchase of biotech firm Acceleron Pharma, the company’s CEO told STAT in an interview Thursday.
But the CEO, Rob Davis, said he also believes that investors have not yet come to realize the value of the experimental drugs Merck is developing.
Continue to STAT+ to read the full story…
